Caisse DE Depot ET Placement DU Quebec Makes New $39.08 Million Investment in Catalent, Inc. (NYSE:CTLT)

Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 645,243 shares of the company's stock, valued at approximately $39,082,000. Caisse DE Depot ET Placement DU Quebec owned about 0.36% of Catalent at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Westchester Capital Management LLC increased its stake in Catalent by 27.9% in the third quarter. Westchester Capital Management LLC now owns 1,445,702 shares of the company's stock valued at $87,566,000 after purchasing an additional 315,525 shares in the last quarter. Public Sector Pension Investment Board increased its position in shares of Catalent by 16.2% in the 3rd quarter. Public Sector Pension Investment Board now owns 7,910 shares of the company's stock valued at $479,000 after buying an additional 1,100 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Catalent by 4.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,024,240 shares of the company's stock worth $62,038,000 after buying an additional 45,564 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Catalent by 12.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,982 shares of the company's stock worth $2,301,000 after acquiring an additional 4,088 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Catalent by 166.5% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company's stock worth $83,733,000 after acquiring an additional 863,624 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CTLT. Robert W. Baird restated a "neutral" rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. StockNews.com downgraded shares of Catalent from a "hold" rating to a "sell" rating in a report on Friday, November 22nd. Finally, William Blair reiterated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $63.40.

Insider Buying and Selling at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company's stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the firm's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company's stock, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock worth $305,931 over the last quarter. 0.31% of the stock is currently owned by insiders.

Catalent Stock Up 0.6 %

NYSE CTLT traded up $0.34 during trading hours on Monday, hitting $61.45. 2,090,967 shares of the company traded hands, compared to its average volume of 2,031,172. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The business's 50-day moving average is $59.93 and its 200-day moving average is $58.55. The stock has a market capitalization of $11.15 billion, a price-to-earnings ratio of -27.19, a P/E/G ratio of 2.43 and a beta of 1.16. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $61.50.

Catalent (NYSE:CTLT - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the company posted ($0.10) EPS. The company's quarterly revenue was up 4.2% compared to the same quarter last year. Sell-side analysts anticipate that Catalent, Inc. will post 0.84 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.